| P2093 | author name string | M Sattler | |
| | J D Griffin | |
| | A Ray | |
| | E Weisberg | |
| P2860 | cites work | The role of FLT3 in haematopoietic malignancies | Q24319174 |
| | Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain | Q27629143 |
| | Structural basis of IAP recognition by Smac/DIABLO | Q27629148 |
| | Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies | Q27824769 |
| | Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor | Q27824787 |
| | A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome | Q27824793 |
| | Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia | Q27824808 |
| | FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). | Q27824823 |
| | Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia | Q27851423 |
| | FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro | Q27851469 |
| | Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition | Q28115131 |
| | A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo | Q28217482 |
| | Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation | Q28242368 |
| | Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 |
| | Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 |
| | Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 |
| | Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. | Q40714821 |
| | FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model | Q40760923 |
| | Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor | Q40792187 |
| | Cell differentiation in acute myeloid leukemia. | Q41027015 |
| | The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells | Q42015052 |
| | A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response | Q42192063 |
| | Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia | Q42742064 |
| | Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms | Q42795736 |
| | Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. | Q42815284 |
| | 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies | Q43078973 |
| | Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice | Q43129559 |
| | CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). | Q44068434 |
| | Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins | Q44117862 |
| | SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase | Q44155418 |
| | SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo | Q44280921 |
| | SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes | Q44370169 |
| | Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia | Q44408358 |
| | Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). | Q44483347 |
| | FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance | Q44484460 |
| | FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins | Q44775125 |
| | Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia | Q44906435 |
| | Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. | Q44922362 |
| | Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Q45042550 |
| | The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors | Q45072250 |
| | Antileukemic activity of rapamycin in acute myeloid leukemia. | Q45154681 |
| | Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. | Q45929224 |
| | KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. | Q45960933 |
| | Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase | Q46426194 |
| | The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia | Q46538314 |
| | CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia | Q46610628 |
| | Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse | Q46705750 |
| | Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib | Q46735050 |
| | Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. | Q46788369 |
| | In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor | Q46832743 |
| | Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene | Q46913925 |
| | The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. | Q46932190 |
| | Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition | Q47422865 |
| | FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress | Q47854939 |
| | Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 |
| | Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. | Q52575669 |
| | Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. | Q53347745 |
| | Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. | Q54067576 |
| | Flt3-dependent transformation by inactivating c-Cbl mutations in AML | Q57269958 |
| | A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia | Q58414438 |
| | Human bone marrow stromal cell contact and soluble factors have different effects on the survival and proliferation of paediatric B-lineage acute lymphoblastic leukaemic blasts | Q72419337 |
| | Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia | Q73208706 |
| | Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene | Q73674699 |
| | Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia | Q73717211 |
| | Bone marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-mediated cell communication | Q73839468 |
| | Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product | Q77299298 |
| | Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes | Q77360733 |
| | Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors | Q79384089 |
| | Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) | Q83154106 |
| | Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study | Q30158055 |
| | An efficient rapid system for profiling the cellular activities of molecular libraries. | Q33234459 |
| | Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor | Q33241590 |
| | Antitumor activity of sorafenib in FLT3-driven leukemic cells | Q33268279 |
| | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors | Q33373888 |
| | Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. | Q33390054 |
| | Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration | Q33494281 |
| | XIAP is not required for human tumor cell survival in the absence of an exogenous death signal | Q33523404 |
| | Altered thymic positive selection and intracellular signals in Cbl-deficient mice | Q33596728 |
| | FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. | Q33680292 |
| | Mll rearrangements in haematological malignancies: lessons from clinical and biological studies | Q33723613 |
| | Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice | Q33776192 |
| | Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance | Q33927591 |
| | Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. | Q34139532 |
| | Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias | Q34335004 |
| | A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy | Q34549807 |
| | 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d | Q34573116 |
| | Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. | Q34578265 |
| | Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens | Q34591403 |
| | Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. | Q34765294 |
| | The roles of FLT3 in hematopoiesis and leukemia | Q34784925 |
| | Origins of chromosome translocations in childhood leukaemia | Q35210004 |
| | ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia | Q35751114 |
| | Clinical implications of FLT3 mutations in pediatric AML. | Q35848876 |
| | FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia | Q35849209 |
| | Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. | Q35849949 |
| | Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia | Q35901705 |
| | Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia | Q36065874 |
| | Negative regulation of PTK signalling by Cbl proteins | Q36194521 |
| | Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. | Q36447942 |
| | Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells | Q36508937 |
| | The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes | Q36508949 |
| | Structural and numerical variation of FLT3/ITD in pediatric AML. | Q36657987 |
| | Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs | Q36854122 |
| | BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair | Q36865331 |
| | Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia | Q36966067 |
| | Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells | Q37003553 |
| | Cytoprotective effects of IAPs revealed by a small molecule antagonist | Q37172657 |
| | Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications | Q37204275 |
| | Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. | Q37234641 |
| | BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair | Q37334605 |
| | Mutations in CBL occur frequently in juvenile myelomonocytic leukemia | Q37334614 |
| | Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome | Q37351733 |
| | AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) | Q37373040 |
| | Mechanisms of resistance to FLT3 inhibitors. | Q37375423 |
| | FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. | Q37495206 |
| | AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. | Q38302335 |
| | A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease | Q39218023 |
| | Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells | Q39745611 |
| | FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression | Q39784014 |
| | Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor | Q39799665 |
| | CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. | Q39874787 |
| | A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. | Q39895136 |
| | Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. | Q39895141 |
| | Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10. | Q39904021 |
| | Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells | Q39960316 |
| | Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias | Q39966770 |
| | Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. | Q39977455 |
| | Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. | Q40025562 |
| | Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations | Q40077336 |
| | A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations | Q40099203 |
| | Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells | Q40109450 |
| | 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors | Q40111543 |
| | BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. | Q40122807 |
| | The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors | Q40182316 |
| | DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. | Q40215417 |
| | Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways | Q40218888 |
| | The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling | Q40220256 |
| | Constitutively activated FLT3 phosphorylates BAD partially through pim-1. | Q40251345 |
| | Splenic endothelial cell lines support development of dendritic cells from bone marrow. | Q40268728 |
| | Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations | Q40294499 |
| | Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia | Q40296363 |
| | Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. | Q40330454 |
| | Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain | Q40390558 |
| | CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. | Q40480723 |
| | RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. | Q40483270 |
| | Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival | Q40501190 |
| | Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). | Q40519489 |
| | Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. | Q40534979 |
| | Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells | Q40618806 |
| | Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. | Q40659303 |
| P433 | issue | 37 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5120-5134 | |
| P577 | publication date | 2010-07-12 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Drug resistance in mutant FLT3-positive AML. | |
| P478 | volume | 29 | |